Emirates Pharmaceutical Corporation announces the withdrawal of the product “Hong Tai Herbal Inhaler (Yiadom)” from the market

The Emirates Pharmaceutical Corporation announced the withdrawal of the Thai inhalant product “Hong Tai Herbal Inhaler (Yiadom)” from the country’s markets after it was proven to be contaminated with microbial substances in a number of its locally circulated batches, in order to ensure the health and safety of patients and society.

This action comes after an official warning issued by the Thai Food and Drug Authority regarding the contamination of one batch of the product, as the institution took immediate steps to ensure the safety of the remaining batches circulating in the country.

The corporation explained that laboratory tests conducted by its quality laboratory on samples withdrawn from the market confirmed the presence of microbial contamination that exceeds the permissible limits for inhalation preparations according to the international pharmacopoeia, which may pose a potential risk to the health of users. Accordingly, a decision was taken to withdraw the product in all its batches from the market, and not only the batches included in the Thai warning.

The Corporation indicated that this procedure comes within the framework of the Corporation’s keenness to protect the health of individuals and ensure the quality and safety of pharmaceutical products circulated in the country, as withdrawals are carried out in coordination with the municipalities and relevant regulatory authorities to ensure the removal of the product from all sales outlets, including electronic stores.

Drug withdrawal procedures
The Foundation works to follow up on the implementation of recalls and ensure their completion through the relevant authorities. It also asks community members not to use the product and dispose of any containers they have.

Emirates Drug Corporation’s strategy for drug security

These measures come within the strategy of the Emirates Drug Corporation, which aims to consolidate the drug security system in the country and ensure the sustainable availability of medicines with the highest standards of quality and safety. The Foundation focuses on building an integrated regulatory system based on proactive risk analysis and monitoring of drug supply chains locally and globally, thus enhancing the country’s ability to respond quickly to any emergency that may affect the availability or safety of the drug.

The Foundation also works within an integrated national system, and in cooperation with federal and local health authorities, to develop policies and legislation that support pharmaceutical security, and to adopt digital solutions and artificial intelligence to track pharmaceutical products from their registration until they reach the consumer.